Improved Glycemic Control with Carbohydrate Counting for Adjustment of Fast-Acting Insulin Aspart vs. Insulin Aspart in Subjects with Type 1 Diabetes

被引：0
|
作者：
Philis-Tsimikas, Athena
Bode, Bruce W.
Franek, Edward
Rose, Ludger
Buchholtz, Kristine
Demissie, Marek
Pieber, Thomas R.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
997-P
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [21] A trial of fast-acting aspart insulin (FIASP) in insulin pumps
    Khan, A. K.
    Weston, P. W. Philip
    Brake, J. B.
    Lamen, L. L.
    Ndebu, J. N.
    Ord, C. O.
    DIABETIC MEDICINE, 2023, 40
  • [22] Faster-Acting Insulin Aspart vs. Insulin Aspart for Adults with Type 1 Diabetes Treated with Insulin Pump and Continuous Glucose Monitoring
    Ranjan, Ajenthen G.
    Schmidt, Signe
    Andersen, Hanne-Charlotte
    Norgaard, Kirsten
    DIABETES, 2024, 73
  • [23] POSTPRANDIAL GLYCEMIC CONTROL WITH FAST-ACTING INSULIN ASPART IN PATIENTS WITH TYPE 1 DIABETES USING SENSOR-AUGMENTED PUMP THERAPY
    Pazos-Couselo, M.
    Garcia-Lopez, J. M.
    Fernandez-Pombo, A.
    Gonzalez-Rodriguez, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A93 - A93
  • [24] The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes
    Biester, Torben
    von Dem Berge, Thekla
    Bendtsen, Line Quist
    Bendtsen, Mette Dahl
    Rathor, Naveen
    Danne, Thomas
    Haahr, Hanne
    PEDIATRIC DIABETES, 2020, 21 (05) : 781 - 790
  • [25] Efficacy and safety of fast-acting insulin aspart in adults with type 2 diabetes with different insulin requirements
    Sesti, G.
    Lane, W.
    Ekelund, M.
    Thorisdottir, O.
    Jodar, E.
    Oviedo, A.
    Rathor, N.
    Senior, P.
    Franek, E.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S330 - S330
  • [26] Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
    Bode, Bruce W.
    Iotova, Violeta
    Kovarenko, Margarita
    Laffel, Lori M.
    Rao, Paturi V.
    Deenadayalan, Srikanth
    Ekelund, Magnus
    Larsen, Steffen Falgreen
    Danne, Thomas
    DIABETES CARE, 2019, 42 (07) : 1255 - 1262
  • [27] Efficacy and safety of fast-acting insulin aspart versus insulin aspart both in combination with insulin degludec with or without metformin in adults with diabetes
    Du, J.
    Wang, G. X.
    Wang, G.
    Liu, M.
    Thamattoor, U. K.
    Luan, Z. J.
    Alibegovic, A. C.
    Mu, Y. M.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S377 - S377
  • [28] GREATER EARLY INSULIN EXPOSURE AND GLUCOSE-LOWERING WITH FASTER-ACTING INSULIN ASPART VS INSULIN ASPART IN JAPANESE SUBJECTS WITH TYPE 1 DIABETES
    Shiramoto, M.
    Nishida, T.
    Hansen, A. K.
    Haahr, H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A118 - A119
  • [29] ONSET 1: EFFICACY AND SAFETY OF MEALTIME FAST-ACTING INSULIN ASPART VERSUS INSULIN ASPART AFTER 52 WEEKS
    Bode, B.
    Mathieu, C.
    Franek, E.
    Philis-Tsimikas, A.
    Rose, L.
    Graungaard, T.
    Osterskov, A. B.
    Russell-Jones, D.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A29 - A29
  • [30] Efficacy and Safety of Fast-Acting Insulin Aspart Are Maintained over 52 Weeks: Comparison with Insulin Aspart in Onset 1
    Mathieu, Chantal
    Bode, Bruce W.
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    DIABETES, 2017, 66 : A258 - A258
12345